Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jens D Lundgren

Showing results (1-10 of 323) with videos related to

Pageof 33
Sort By:
Evidence-Based Nursing|September 3, 2013
People with HIV are at increased risk of acute myocardial infarctionJens D Lundgren
Pharmacoepidemiology and Drug Safety|August 6, 2003
Dyslipidaemia and cardiovascular disease risk associated with antiretroviral drugsJens D Lundgren
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 20, 2009
Use of risk equations for predicting disease progression in HIV infectionAmanda Mocroft, Jens D Lundgren
International Journal of Epidemiology|January 15, 2005
Commentary: Death in the era of potent antiretroviral therapy: shifting causes, new challengesMarcel Zwahlen, Jens D Lundgren
Journal of HIV Therapy|September 20, 2006
The impact of antiretroviral therapy on AIDS and survivalJens D Lundgren, Amanda Mocroft
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 14, 2013
Editorial commentary: universal antiretroviral therapy for HIV infection?Jens D Lundgren, Robin Wood
Current Opinion in Infectious Diseases|April 20, 2004
Clinical trial methodology and clinical cohorts: the importance of complete follow-up in trials evaluating the virological efficacy of anti-HIV medicinesOle Kirk, Jens D Lundgren
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 29, 2003
Anemia and survival in human immunodeficiency virusJens D Lundgren, Amanda Mocroft
Lancet (London, England)|February 14, 2014
Antiretroviral dose reduction: good for patients and rolloutJens D Lundgren, Andrew Phillips
The Journal of Antimicrobial Chemotherapy|May 28, 2004
Starting highly active antiretroviral therapy: why, when and response to HAARTAmanda Mocroft, Jens D Lundgren
Pageof 33

Showing results (1-10 of 323) with videos related to

Sort By:
Pageof 33
Evidence-Based Nursing|September 3, 2013
People with HIV are at increased risk of acute myocardial infarctionJens D Lundgren
Pharmacoepidemiology and Drug Safety|August 6, 2003
Dyslipidaemia and cardiovascular disease risk associated with antiretroviral drugsJens D Lundgren
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 20, 2009
Use of risk equations for predicting disease progression in HIV infectionAmanda Mocroft, Jens D Lundgren
International Journal of Epidemiology|January 15, 2005
Commentary: Death in the era of potent antiretroviral therapy: shifting causes, new challengesMarcel Zwahlen, Jens D Lundgren
Journal of HIV Therapy|September 20, 2006
The impact of antiretroviral therapy on AIDS and survivalJens D Lundgren, Amanda Mocroft
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 14, 2013
Editorial commentary: universal antiretroviral therapy for HIV infection?Jens D Lundgren, Robin Wood
Current Opinion in Infectious Diseases|April 20, 2004
Clinical trial methodology and clinical cohorts: the importance of complete follow-up in trials evaluating the virological efficacy of anti-HIV medicinesOle Kirk, Jens D Lundgren
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 29, 2003
Anemia and survival in human immunodeficiency virusJens D Lundgren, Amanda Mocroft
Lancet (London, England)|February 14, 2014
Antiretroviral dose reduction: good for patients and rolloutJens D Lundgren, Andrew Phillips
The Journal of Antimicrobial Chemotherapy|May 28, 2004
Starting highly active antiretroviral therapy: why, when and response to HAARTAmanda Mocroft, Jens D Lundgren
Pageof 33